Investigational Drug Targets Sleep Apnea and Nocturnal Hypertension
A phase 2 trial will evaluate the drug’s potential to reduce upper airway obstruction and nocturnal hypertension in patients with moderate-to-severe OSA.
A phase 2 trial will evaluate the drug’s potential to reduce upper airway obstruction and nocturnal hypertension in patients with moderate-to-severe OSA.
